Evenity (Romosozumab) Adolescent (12 to 17) Caregiver Administration Guidance

What Is Romosozumab and Why Might an Adolescent Need It?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein that normally suppresses bone formation. By blocking sclerostin, the drug simultaneously increases bone formation and decreases bone resorption, a dual mechanism not seen in bisphosphonates or denosumab. The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high fracture risk, and off-label or investigational use in adolescents has been examined for conditions causing severe secondary osteoporosis. [1]

Conditions That May Lead to Adolescent Prescription

Adolescents may be prescribed romosozumab under specialist supervision for rare conditions including osteogenesis imperfecta, glucocorticoid-induced osteoporosis refractory to bisphosphonates, or other high-fracture-risk skeletal dysplasias. A 2021 review in the Journal of Clinical Endocrinology and Metabolism described the investigational use of sclerostin inhibitors in pediatric bone disorders, noting that bone anabolic agents address the unmet need left by antiresorptive therapies alone. [2]

How the Mechanism Differs From Other Bone Drugs

Standard antiresorptive agents such as alendronate or zoledronic acid slow bone loss but do not actively build new bone. Romosozumab's anabolic-then-antiresorptive profile means caregivers must understand that the 12-month course is time-limited by design. After the 12th dose, the prescriber will transition the adolescent to a maintenance antiresorptive agent to preserve gains. [3]

What Caregivers Need to Know Before the First Injection

Before a caregiver gives the first dose, the prescribing physician must confirm that the adolescent's serum calcium is within the normal reference range. Hypocalcemia is listed in the FDA prescribing information as a contraindication, and administering romosozumab to a hypocalcemic patient can worsen the deficit and trigger symptomatic tetany. [1]

Pre-Administration Checklist

Caregivers should complete the following before each monthly administration session:

• Confirm the patient has adequate calcium and vitamin D intake (the FDA label recommends supplementation throughout treatment). [1]
• Inspect both pre-filled syringes: the solution should be colorless to pale yellow and free of visible particles.
• Remove both syringes from the refrigerator 20 to 30 minutes before injection so they reach room temperature, which reduces injection discomfort.
• Wash hands thoroughly with soap and water for at least 20 seconds.
• Gather supplies: alcohol swabs, gauze or cotton ball, a sharps disposal container.

Cardiovascular History Review

The FDA label carries a boxed warning: romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Do not administer Evenity to an adolescent who has had a myocardial infarction or stroke within the preceding 12 months. If the adolescent has known atherosclerotic cardiovascular disease or multiple cardiovascular risk factors, the prescriber must weigh the risk-benefit profile before initiating therapy. [1]

The ARCH trial (N=4,093) in postmenopausal women found that the romosozumab arm had a higher rate of serious cardiovascular adverse events compared with alendronate (2.5% vs. 1.9%), which formed the basis of the boxed warning. [4] Caregivers of adolescents with congenital heart disease or other cardiovascular comorbidities must report any chest pain, shortness of breath, or sudden neurological symptoms to the prescriber immediately.

Step-by-Step Injection Procedure

Each monthly dose consists of two separate 105 mg subcutaneous injections given consecutively in the same session. The two injections should not be given at the same site. Follow this sequence for every administration. [1]

Step 1: Site Selection and Preparation

Choose one of three approved injection regions:

1. Abdomen: at least 2 inches (5 cm) away from the navel; avoid the waistband area.
2. Anterior thigh: the outer middle portion of either thigh.
3. Outer upper arm: only suitable if a second person is administering; the adolescent cannot self-inject this site safely.

Rotate sites each month to reduce the risk of lipodystrophy and injection-site reactions. Clean the chosen spot with an alcohol swab and allow it to dry completely before inserting the needle. [1]

Step 2: Injection Technique

Pick up the first pre-filled autoinjector. Remove the cap immediately before use. Do not recap. Pinch the skin lightly if the adolescent has minimal subcutaneous tissue. Press the autoinjector firmly against the skin at a 90-degree angle until the skin contact guard is fully depressed. Press and hold the plunger button until you hear a click, then keep the device pressed against the skin for an additional 5 seconds to ensure full delivery. Withdraw the device straight out. The needle guard will automatically extend.

Repeat the identical process at an adjacent or separate site using the second autoinjector. Both injections must be completed within the same visit. [1]

Step 3: Post-Injection Care

Apply light pressure with gauze or a cotton ball. Do not rub the injection site, as rubbing can cause local irritation. Dispose of both used autoinjectors immediately in a sharps container. Do not place them in household waste or recycling bins. [5]

Storage and Handling Rules

Proper cold-chain management directly affects drug potency. Romosozumab pre-filled syringes must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). [1]

Refrigeration and Room-Temperature Limits

| Condition | Allowable Duration | |---|---| | Refrigerated (2°C to 8°C) | Until expiration date on carton | | Room temperature (up to 25°C / 77°F) | Maximum 30 days | | Frozen | Never; discard if accidentally frozen | | Exposed to direct light | Avoid; keep in original carton |

Once a syringe has been removed from the refrigerator and reaches room temperature, it must be used within 30 days or discarded. Caregivers should write the date of removal on the carton with a permanent marker. [1]

Travel Considerations

When traveling, transport syringes in an insulated cooler bag with ice packs. Do not allow the syringes to contact ice directly, as freezing will compromise the formulation. At the destination, transfer syringes to a refrigerator as soon as possible. The 30-day room-temperature window applies continuously from the moment of first removal from refrigeration, not from arrival at the destination. [1]

Calcium and Vitamin D Requirements During Treatment

Romosozumab's anabolic activity can transiently lower serum calcium because new bone matrix rapidly incorporates calcium. The FDA label recommends that all patients receive adequate calcium and vitamin D supplementation throughout the 12-month treatment course. [1]

Recommended Intake Targets

The National Institutes of Health Office of Dietary Supplements sets calcium requirements for adolescents aged 14 to 18 at 1,300 mg/day and vitamin D at 600 IU/day as the recommended dietary allowance, though many practitioners prescribe higher vitamin D doses (1,000 to 2,000 IU/day) in patients with documented insufficiency. [6] Caregivers should confirm the adolescent's supplementation regimen at each monthly visit.

Signs of Hypocalcemia to Watch For

Symptoms that may indicate low calcium include:

• Muscle cramps or spasms, especially in the hands, feet, or face
• Tingling or numbness around the mouth or in the fingertips
• Seizures in severe cases
• Unusual fatigue or confusion

Report any of these signs to the prescriber before administering the next monthly dose. Serum calcium should be checked if symptoms arise. [1]

Managing Missed or Delayed Doses

If a monthly dose is missed, the caregiver should administer it as soon as the omission is recognized, then reschedule subsequent doses one month from that administration date. Do not double up by giving two doses on the same day to compensate. [1]

The prescribing information does not define a specific maximum delay beyond which the dose should be skipped, but prolonged gaps (greater than 6 to 8 weeks between doses) may reduce the cumulative anabolic effect. Caregivers should contact the prescribing physician if a dose is delayed more than 2 weeks past the scheduled date so the physician can advise on whether to adjust the remaining treatment timeline.

Adverse Effects Caregivers Must Recognize

Injection-Site Reactions

The most common adverse effects reported in clinical trials were injection-site pain (reported in approximately 5% of participants in the FRAME trial, N=7,180), redness, and swelling. [7] These typically resolve within 24 to 48 hours. Applying a cold pack before injection may reduce discomfort for adolescents who are needle-sensitive.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is a rare but serious adverse effect associated with bone-active agents, including romosozumab. The FDA label recommends that patients maintain good oral hygiene and complete any invasive dental procedures (extractions, implants) before starting treatment or, if unavoidable, during a treatment gap. [1] Caregivers should inform the adolescent's dentist about the romosozumab regimen before any dental work.

Atypical Femoral Fractures

Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bone-active agents. Caregivers should report new or worsening thigh, hip, or groin pain to the prescriber. [1] Bilateral X-ray evaluation is warranted if such symptoms develop.

Hypersensitivity Reactions

Rare cases of hypersensitivity, including angioedema and dermatitis, have been reported. If the adolescent develops urticaria, facial swelling, or difficulty breathing within minutes to hours of an injection, call emergency services and do not administer further doses until the prescriber has evaluated the reaction. [1]

Talking With Your Adolescent About the Injections

Adolescents aged 12 to 17 respond better to medical procedures when they understand the rationale and feel some control over the process. A practical framework for caregiver-adolescent communication around monthly injections includes three phases:

Before the injection (1 to 2 days prior): Let the adolescent choose the injection site from the approved options. Discuss the schedule together so the date is not a surprise. If the adolescent has anxiety around needles, contact the prescriber about topical anesthetic cream (e.g., EMLA cream applied 60 minutes before injection). [8]

During the injection: Encourage slow, steady breathing. The autoinjector click can startle some patients; demonstrate the sound on a practice surface beforehand. Keep conversation neutral and calm. Avoid phrases like "this will hurt" or "almost done" on repeat, as repetition increases anticipatory anxiety per pediatric pain research. [9]

After the injection: Acknowledge the adolescent's cooperation specifically, rather than generically praising bravery. Ask if they noticed anything unusual (local pain, tingling, dizziness) and document it in a simple logbook. The logbook becomes a useful clinical record at follow-up appointments.

Monitoring Schedule During the 12-Month Course

Caregivers should coordinate with the prescribing specialist to maintain the following monitoring cadence:

| Timepoint | Test or Assessment | |---|---| | Before first dose | Serum calcium, phosphorus, 25-OH vitamin D | | Monthly (each visit) | Blood pressure, review of cardiovascular symptoms | | At months 3 and 6 | Serum calcium if symptomatic or dietary intake unclear | | At month 12 (end of course) | DXA bone mineral density; transition plan to antiresorptive therapy |

A 2022 position statement from the Endocrine Society noted that bone mineral density monitoring via DXA is the standard method for tracking skeletal response to anabolic therapy and should be performed at baseline and at the conclusion of the anabolic course. [10]

Transitioning After the 12-Month Course

Romosozumab treatment is limited to 12 monthly doses because the anabolic effect diminishes with continued use, a phenomenon attributed to compensatory increases in bone resorption markers. [3] At month 12, the prescribing physician will discuss transitioning to an antiresorptive agent, most commonly a bisphosphonate or denosumab, to preserve the bone mineral density gained during the romosozumab course.

Abruptly stopping bone-active therapy without transition carries a risk of rapid bone loss. In adults, denosumab discontinuation without follow-up therapy has been associated with rebound vertebral fractures; similar caution applies to the anabolic-to-antiresorptive transition for romosozumab. [11] Caregivers should ensure the follow-up prescription is in place before the final romosozumab dose is administered.